Core Insights - XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on innovative therapies for gout and progressive kidney disease [1] - The company held its annual and special meeting of shareholders on March 24, 2026, where all proposed matters were approved [2] Company Overview - XORTX has three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury related to respiratory virus infections [3] - Additionally, the company is developing XRx-225, a pre-clinical program targeting Type 2 diabetic nephropathy [3] - The company aims to improve the quality of life for individuals with gout and other significant diseases by targeting purine metabolism and xanthine oxidase to reduce uric acid production [3] Shareholder Meeting Outcomes - A total of 2,407,148 common shares were represented at the meeting, accounting for approximately 35% of the total shares issued and outstanding [2] - All five management nominees were elected to the board of directors, and Davidson & Company LLP was appointed as auditors for the upcoming year [2] - The stock option plan was re-approved, and a share consolidation was authorized [2]

Core Viewpoint - STMicroelectronics has announced the resolutions to be proposed at the 2026 Annual General Meeting of Shareholders, scheduled for May 27, 2026, in Amsterdam, which includes key financial and governance decisions [2]. Group 1: AGM Resolutions - The record date for shareholders to participate in the AGM is set for April 29, 2026 [2]. - The adoption of the statutory annual accounts for the year ended December 31, 2025, prepared in accordance with International Financial Reporting Standards (IFRS) [6]. - A cash dividend of US$ 0.36 per outstanding share will be distributed in quarterly installments of US$ 0.09 for the second, third, and fourth quarters of 2026, and the first quarter of 2027 [6]. - The reappointment of Mr. Frédéric Sanchez to the Supervisory Board for a three-year term expiring at the end of the 2029 AGM [6]. - Approval of stock-based compensation for the President and CEO, and the President and CFO [6]. - Authorization for the Managing Board to repurchase shares until the conclusion of the 2027 AGM, subject to Supervisory Board approval [6]. - Delegation of authority to the Supervisory Board to issue new common shares and limit or exclude existing shareholders' pre-emptive rights until the end of the 2027 AGM [6]. - Discharge of members of the Managing Board and Supervisory Board [6]. Group 2: Dividend Schedule - The ex-dividend date for Q2 2026 is June 22, 2026, with a record date of June 23, 2026, and payment on June 24, 2026 [3]. - The ex-dividend date for Q3 2026 is September 21, 2026, with a record date of September 22, 2026, and payment on September 23, 2026 [3]. - The ex-dividend date for Q4 2026 is December 14, 2026, with a record date of December 15, 2026, and payment on December 16, 2026 [3]. - The ex-dividend date for Q1 2027 is March 15, 2027, with a record date of March 16, 2027, and payment on March 17, 2027 [3]. Group 3: Company Overview - STMicroelectronics employs 48,000 individuals and operates state-of-the-art manufacturing facilities, serving over 200,000 customers [4]. - The company aims to achieve carbon neutrality in all direct and indirect emissions and to source 100% renewable electricity by the end of 2027 [4].

Core Viewpoint - Datacentrex, Inc. has announced a public offering of common stock priced at $2.00 per share, aiming to raise approximately $20.17 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes common stock and pre-funded warrants, with expected gross proceeds of $20.17 million before fees and expenses [2]. - The offering is anticipated to close on or about March 30, 2026, pending customary closing conditions [2]. - The offering is conducted under a shelf registration statement filed with the SEC, which was declared effective on May 30, 2025 [3]. Group 2: Company Overview - Datacentrex operates in the digital infrastructure sector, focusing on Scrypt compute assets and strategic transactions in asset-backed businesses [6]. - The company monetizes its compute primarily through hashrate marketplace mechanisms and manages a treasury of digital assets and cash to support capital preservation and opportunistic deployment [6].

Core Viewpoint - QDRO Acquisition Corp. has announced the pricing of its initial public offering (IPO) of 20,000,000 units at $10.00 per unit, with trading set to begin on March 27, 2026 under the ticker symbol "QADRU" [1] Group 1: IPO Details - Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with whole warrants exercisable at $11.50 per share [1] - The offering is expected to close on March 30, 2026, subject to customary closing conditions [2] - Cantor Fitzgerald & Co. is the sole bookrunner for the offering and has been granted a 45-day option to purchase an additional 3,000,000 units to cover over-allotments [2] Group 2: Company Focus - QDRO Acquisition Corp. is a blank check company formed to effect a merger or similar business combination, focusing on businesses in the financial services, digital currency, and technology sectors [5]

Core Viewpoint - Firan Technology Group Corporation (FTG) is set to release its first quarter 2026 financial results on April 8, 2026, and will host a conference call on April 9, 2026, to discuss these results [1]. Company Overview - FTG operates as a supplier of aerospace and defense electronics products and subsystems globally, with two main operating units: FTG Circuits and FTG Aerospace [3][4]. - FTG Circuits specializes in manufacturing high technology, high reliability printed circuit boards for leaders in aviation, defense, and high technology industries, with operations in multiple locations including Toronto, California, Virginia, Minnesota, Massachusetts, and a joint venture in Tianjin, China [3]. - FTG Aerospace focuses on designing, certifying, manufacturing, and providing support for illuminated cockpit products and electronic assemblies for original equipment manufacturers and operators in the aerospace and defense sectors, with operations in Toronto, Calgary, California, and Tianjin [4]. Financial Communication - The conference call for discussing the financial results will be led by Chairperson Mr. Brad Bourne, and participants can join by dialing specific numbers provided in the announcement [2]. - A replay of the conference call will be available until May 11, 2026, and can be accessed through FTG's website [2].

Core Insights - Lassonde Industries Inc. reported strong financial performance for the fourth quarter and the year ended December 31, 2025, with significant increases in sales, gross profit, and net income despite a challenging macroeconomic environment [2][4][8] Financial Highlights - Fourth quarter sales reached $768.1 million, an increase of $30.0 million (4.1%) compared to the same quarter in 2024, driven by price adjustments in Canada and higher sales volume in the U.S. [4][5] - Gross profit for the fourth quarter was $225.0 million, representing 29.3% of sales, up $32.1 million from the previous year [4][5] - Operating profit increased to $71.1 million, up $28.1 million from the same quarter last year [4][5] - Profit attributable to shareholders was $54.0 million, resulting in an EPS of $7.92, a 99.2% increase from the same quarter in 2024 [4][5] - Adjusted EBITDA for the fourth quarter was $101.8 million, up 27.9% from the previous year [4][5] Fiscal Year Highlights - Total sales for the year were $2,934.0 million, an increase of $333.1 million (12.8%) from 2024, with a favorable foreign exchange impact of $28.8 million [4][5] - Gross profit for the year was $801.5 million, or 27.3% of sales, up $103.4 million from the previous year [4][5] - Operating profit for the year reached $226.1 million, an increase of $51.4 million from 2024 [4][5] - Profit attributable to shareholders for the year was $149.7 million, resulting in an EPS of $21.94, a 31.1% increase from 2024 [4][5] Outlook - The company anticipates continued sales growth in 2026, aiming to reach $3 billion in sales, supported by pricing actions and volume expansion [8][13] - Key factors influencing performance include consumer financial health and inflationary pressures, alongside geopolitical uncertainties [8][13] - The effective tax rate for 2026 is estimated to be approximately 22.5% [15] - Capital expenditures for 2026 are projected to be up to 7.0% of sales, including approximately US$96 million for a new plant in New Jersey [19]

Company Overview - Rumble Inc. is a high-growth neutral video platform and cloud services provider, offering products such as Rumble Video, Rumble Studio, Rumble Advertising Center, Rumble Wallet, and Rumble Cloud [5] Leadership Change - Mike Masci has been appointed as the new CFO of Rumble, effective March 31, 2026, succeeding Brandon Alexandroff, who will transition to a strategic advisor role [1] - Brandon Alexandroff has played a crucial role in the company's growth and will continue to contribute in his new position [4] New CFO's Background - Mike Masci is a seasoned technology executive with extensive experience in AI and cloud infrastructure, previously serving as Vice President of Product Management for the Edge Computing Group at Intel [2] - His experience includes leading large-scale, high-growth technology businesses and holding the position of Group CFO for the Datacenter Network Platforms Group at Intel [2][3] - Masci's expertise covers areas such as Hyperscale Cloud, Edge and Enterprise Datacenters, Infrastructure-as-a-Service, and Generative AI [3] Strategic Vision - The CEO of Rumble, Chris Pavlovski, expressed excitement about Masci's appointment, highlighting his financial and AI industry experience as key to supporting Rumble's growth and scaling of its platform and cloud services [4] - The company is looking forward to leveraging AI infrastructure opportunities, particularly in relation to its pending acquisition of Northern Data [4]

Core Insights - LeonaBio has acquired a license for the Phase 3 development of lasofoxifene, a selective estrogen receptor modulator (SERM), which presents a potential multi-billion dollar opportunity for treating breast cancer patients with ESR1 mutations [1][5][3] - The company raised $90 million through private placement financing, with the potential for an additional $146 million from cash-exercisable warrants to support the development of lasofoxifene [1][3] - The Phase 3 clinical trial for lasofoxifene is expected to complete enrollment by Q4 2026, with topline data anticipated in the second half of 2027 [2][5] Clinical Development & Pipeline Programs - Lasofoxifene is designed to target both wild-type and mutant estrogen receptors, particularly for patients with ESR1 mutations who have limited treatment options [4][5] - The ongoing Phase 3 ELAINE-3 trial aims to establish a new standard of care for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with an amendment to increase the sample size from 500 to 600 participants [5][4] - ATH-1105, another drug candidate, is being developed for ALS and is on track to initiate a Phase 2 proof-of-concept study in the second half of 2026 [2][6] Corporate Updates - The company transitioned from Athira Pharma to LeonaBio, reflecting a strategic evolution towards a more focused and diversified biopharmaceutical entity [3] - Mark F. Kubik was appointed as Chief Business Officer to oversee licensing and corporate development initiatives [6] - The name change aligns with the acquisition of lasofoxifene rights and emphasizes the company's commitment to innovation in treating unmet medical needs [6] Financial Results - As of December 31, 2025, LeonaBio reported cash and cash equivalents of $69.3 million, an increase from $48.4 million in 2024 [17] - Research and development expenses rose to $85.6 million in 2025, primarily due to costs associated with the lasofoxifene license [10][8] - The net loss for 2025 was $105.6 million, or $24.70 per share, compared to a net loss of $96.9 million, or $25.19 per share, in 2024 [14][21]

Core Insights - DBV Technologies reported its financial results for the full year 2025, focusing on advancing its clinical development programs and preparing for the commercialization of the VIASKIN® Peanut Patch [2][3] Financial Performance - Operating income for 2025 was $5.6 million, an increase from $4.2 million in 2024, attributed to higher eligible activities for the French Research Tax Credit [11] - Research and Development (R&D) expenses rose by $27.3 million in 2025 compared to 2024, reflecting increased investment in clinical programs [12] - Selling, General and Administrative (SG&A) expenses increased by $4.6 million in 2025, primarily due to market research activities and operational enhancements for the VIASKIN® Peanut Patch launch [12] - The net loss for 2025 was $147.0 million, compared to $113.9 million in 2024, with a net loss per share of $1.05 for 2025 [13] - Cash and cash equivalents stood at $194 million as of December 31, 2025, a significant increase from $32.5 million in 2024, with net cash used for operating activities at $121.2 million [14] Operational Highlights - The company advanced its clinical development programs for the VIASKIN® Peanut Patch in peanut-allergic toddlers and children, reporting positive topline results from the Phase 3 VITESSE trial [8][10] - A supplemental safety study, COMFORT Toddlers, was initiated for peanut-allergic toddlers aged 1 to 3 years [8] - The company appointed new executives to strengthen its leadership team in preparation for the potential commercialization of the VIASKIN® Peanut Patch [9] Anticipated Events - The company plans to submit a Biologics License Application (BLA) for children aged 4 to 7 years in the first half of 2026, with a potential for Priority Review [15] - Completion of enrollment for the COMFORT Toddlers safety study is expected, with topline results anticipated [15] - A BLA submission for 1-3 year olds is anticipated in the second half of 2026 under an Accelerated Approval Pathway [15]

Group 1 - The Company, Future Money Acquisition Corporation, has announced the pricing of its initial public offering (IPO) of 10,000,000 units at a price of $10.00 per unit, with trading set to begin on March 27, 2026 [1] - Each unit consists of one ordinary share and one right to receive one-fifth (1/5) of an ordinary share upon the completion of the Company's initial business combination [1] - The offering is expected to close on March 30, 2026, subject to customary closing conditions [1] Group 2 - The Company is a blank check company incorporated in the Cayman Islands, aiming to enter into a business combination with one or more businesses or entities across various industries and geographic regions [2] - The Company's sponsor is Future Wealth Capital Corp., a British Virgin Islands business company, with Mr. Siyu Li as the ultimate beneficial owner [2] Group 3 - D. Boral Capital is acting as the sole book-running manager for the offering and has been granted a 45-day option to purchase up to an additional 1,500,000 units at the IPO price to cover over-allotments [3] Group 4 - A registration statement on Form S-1 relating to the units and underlying securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on March 26, 2026 [4]